| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T147 |
0-6 |
Sentence |
denotes |
3.7.3. |
| T148 |
7-16 |
Sentence |
denotes |
Treatment |
| T149 |
17-132 |
Sentence |
denotes |
Both SARS-CoV and SARS-CoV-2 are CoVs; hence, the treatment strategies of SARS could be relevant for COVID-19 [74]. |
| T150 |
133-317 |
Sentence |
denotes |
In 2003, SARS was mainly treated by isolation of the patients, hormones treatment, antiviral and symptomatic treatments, and many drugs such as glucocorticoid [29] and interferon [75]. |
| T151 |
318-420 |
Sentence |
denotes |
Now, isolation, antiviral, and symptomatic treatments are still mainly adopted for COVID-19 treatment. |
| T152 |
421-515 |
Sentence |
denotes |
As effective drugs for SARS, hormones and interferons can also be used to treat COVID-19 [74]. |
| T153 |
516-617 |
Sentence |
denotes |
Lopinavir is one kind of protease inhibitor used to treat HIV infection, with ritonavir as a booster. |
| T154 |
618-684 |
Sentence |
denotes |
Lopinavir and/or ritonavir has anti coronavirus activity in vitro. |
| T155 |
685-900 |
Sentence |
denotes |
Hong Kong scholars found that, compared with ribavirin alone, patients treated with lopinavir/ritonavir and ribavirin had lower risk of acute respiratory distress syndrome (ARDS) or death caused by SARS-CoV [76,77]. |
| T156 |
901-1102 |
Sentence |
denotes |
Lopinavir/ritonavir has also been clinically tested in treatment of COVID-19, and showed wonderfully effective treatment for some patients, but the general clinical effect has not been determined [78]. |
| T157 |
1103-1168 |
Sentence |
denotes |
More effective treatments are still under continuing exploration: |
| T158 |
1169-1176 |
Sentence |
denotes |
On Jan. |
| T159 |
1177-1417 |
Sentence |
denotes |
25th, 2020, a joint research team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Shanghai Tech University screened and identified 30 potential drugs that are reported to be effective against SARS-CoV-2 [79]. |
| T160 |
1418-1667 |
Sentence |
denotes |
A high-resolution crystal structure of SARS-CoV-2 coronavirus 3CL hydrolase (Mpro) was announced after the outbreak of COVID-19 in the world [80], and human coronaviruses (HCoVs) have been treated as severe pathogens in respiratory tract infections. |
| T161 |
1668-1754 |
Sentence |
denotes |
Nelfinavir was predicted to be a potential inhibitor of SARS-CoV-2 main protease [81]. |
| T162 |
1755-1921 |
Sentence |
denotes |
The first patient in the US had been trial-treated with intravenous remdesivir (a novel nucleotide analogue prodrug in development) due to a severe infection [82,83]. |
| T163 |
1922-2042 |
Sentence |
denotes |
No adverse reactions were observed during the administration, and the patient’s condition was effectively improved [84]. |
| T164 |
2043-2119 |
Sentence |
denotes |
Clinical trials of remdesivir for treatment of COVID-19 just started on Feb. |
| T165 |
2120-2227 |
Sentence |
denotes |
5th and 12th, 2020 in Wuhan and Beijing, respectively, and the experimental results remain unclear [85,86]. |
